Human immune deficiency virus (HIV) infection and the hypothalamic pituitary adrenal axis

Reviews in Endocrine and Metabolic Disorders

Volumn 14, Issue 2, 2013, Pages 105-112

  George, Minu M ^a   Bhangoo, Amrit ^b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b KINGS COUNTY HOSPITAL CENTER   (United States)

Author keywords

AIDS; Cortisol; Cytokines; Glucocorticoids; HIV; HPA axis

Indexed keywords

GAMMA INTERFERON; GLYCOPROTEIN GP 120; HEAT SHOCK PROTEIN 90; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; LOPINAVIR; RITONAVIR; TRANSCORTIN; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ADRENAL CORTEX FUNCTION; ADRENAL FUNCTION; ADRENAL INSUFFICIENCY; ADRENAL MEDULLA; ADRENAL SUPPRESSION; ARTICLE; BINDING AFFINITY; CD4+ T LYMPHOCYTE; DISEASE COURSE; DNA BINDING; FEEDBACK SYSTEM; GENE EXPRESSION; HISTOPLASMA CAPSULATUM; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNE RESPONSE; IMMUNOMODULATION; MYCOBACTERIUM AVIUM; MYCOBACTERIUM TUBERCULOSIS; PLASMA RENIN ACTIVITY; SIGNAL TRANSDUCTION; STRESS; TH1 TH2 BALANCE;

ADRENAL INSUFFICIENCY; CYTOKINES; GLUCOCORTICOIDS; HIV; HIV INFECTIONS; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MODELS, BIOLOGICAL; PITUITARY-ADRENAL SYSTEM;

EID: 84879696613     PISSN: 13899155     EISSN: 15732606     Source Type: Journal    
DOI: 10.1007/s11154-013-9244-x     Document Type: Article

References (68)

1. UNAIDS/WHO.: AIDS epidemic update. Edited by 2009, p.
2. Grinspoon SK, Bilezikian JP. HIV disease and the endocrine system. N Engl J Med. 1992;327:1360-5.
3. Eledrisi MS, Verghese AC. Adrenal insufficiency in HIV infection: a review and recommendations. Am J Med Sci. 2001;321:137-44.
4. Shashidhar PK, Shashikala GV. Low dose adrenocorticotropic hormone test and adrenal insufficiency in critically ill acquired immunodeficiency syndrome patients. Indian J Endocrinol Metab. 2012;16:389-94.
5. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med. 1995;332:1351-62.
6. Chrousos GP, Gold PW. The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. JAMA. 1992;267:1244-52.
7. Rivier C, Brownstein M, Spiess J, Rivier J, Vale W. In vivo corticotropin-releasing factor-induced secretion of adrenocorticotropin, beta-endorphin, and corticosterone. Endocrinology. 1982;110:272-8.
8. Vale W, Spiess J, Rivier C, Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science. 1981;213:1394-7.
9. Conaglen JV, Donald RA, Espiner EA, Livesey JH, Nicholls MG. The effect of ovine corticotropin-releasing factor on catecholamine, vasopressin, and aldosterone secretion in normal man. J Clin Endocrinol Metab. 1984;58:463-6.
10. Dittmar KD, Demady DR, Stancato LF, Krishna P, Pratt WB. Folding of the glucocorticoid receptor by the heat shock protein (hsp) 90-based chaperone machinery. The role of p23 is to stabilize receptor.hsp90 heterocomplexes formed by hsp90.p60.hsp70. J Biol Chem. 1997;272:21213-20.
11. Dittmar KD, Pratt WB. Folding of the glucocorticoid receptor by the reconstituted Hsp90-based chaperone machinery. The initial hsp90.p60.hsp70- dependent step is sufficient for creating the steroid binding conformation. J Biol Chem. 1997;272:13047-54.
12. Pratt WB, Toft DO. Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev. 1997;18:306-60.
13. Cheung J, Smith DF. Molecular chaperone interactions with steroid receptors: an update. Mol Endocrinol. 2000;14:939-46.
14. Davies TH, Ning YM, Sanchez ER. A new first step in activation of steroid receptors: hormone-induced switching of FKBP51 and FKBP52 immunophilins. J Biol Chem. 2002;277:4597-600.
15. Wochnik GM, Ruegg J, Abel GA, Schmidt U, Holsboer F, Rein T. FK506-binding proteins 51 and 52 differentially regulate dynein interaction and nuclear translocation of the glucocorticoid receptor in mammalian cells. J Biol Chem. 2005;280:4609-16.
16. Sakai DD, Helms S, Carlstedt-Duke J, Gustafsson JA, Rottman FM, Yamamoto KR. Hormone-mediated repression: a negative glucocorticoid response element from the bovine prolactin gene. Genes Dev. 1988;2:1144-54.
17. Drouin J, Trifiro MA, Plante RK, Nemer M, Eriksson P, Wrange O. Glucocorticoid receptor binding to a specific DNA sequence is required for hormone-dependent repression of pro-opiomelanocortin gene transcription. Mol Cell Biol. 1989;9:5305-14.
18. Ray A, Prefontaine KE. Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor. Proc Natl Acad Sci U S A. 1994;91:752-6.
19. Stocklin E, Wissler M, Gouilleux F, Groner B. Functional interactions between Stat5 and the glucocorticoid receptor. Nature. 1996;383:726-8.
20. Croxtall JD, Choudhury Q, Flower RJ. Glucocorticoids act within minutes to inhibit recruitment of signalling factors to activated EGF receptors through a receptor-dependent, transcription-independent mechanism. Br J Pharmacol. 2000;130:289-98.
21. Gross KL, Cidlowski JA. Tissue-specific glucocorticoid action: a family affair. Trends Endocrinol Metab. 2008;19:331-9.
22. Guarda LA, Luna MA, Smith Jr JL, Mansell PW, Gyorkey F, Roca AN. Acquired immune deficiency syndrome: postmortem findings. Am J Clin Pathol. 1984;81:549-57.
23. Tapper ML, Rotterdam HZ, Lerner CW, Al'Khafaji K, Seitzman PA. Adrenal necrosis in the acquired immunodeficiency syndrome. Ann Intern Med. 1984;100:239-41.
24. Guenthner EE, Rabinowe SL, Van Niel A, Naftilan A, Dluhy RG. Primary Addison's disease in a patient with the acquired immunodeficiency syndrome. Ann Intern Med. 1984;100:847-8.
25. Greene LW, Cole W, Greene JB, Levy B, Louie E, Raphael B, et al. Adrenal insufficiency as a complication of the acquired immunodeficiency syndrome. Ann Intern Med. 1984;101:497-8.
26. Staras SA, Dollard SC, Radford KW, Flanders WD, Pass RF, Cannon MJ. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2006;43:1143-51.
27. Hoshino Y, Nagata Y, Gatanaga H, Hosono O, Morimoto C, Tachikawa N, et al. Cytomegalovirus (CMV) retinitis and CMV antigenemia as a clue to impaired adrenocortical function in patients with AIDS. AIDS. 1997;11:1719-24.
28. Glasgow BJ, Steinsapir KD, Anders K, Layfield LJ. Adrenal pathology in the acquired immune deficiency syndrome. Am J Clin Pathol. 1985;84:594-7.
29. Arabi Y, Fairfax MR, Szuba MJ, Crane L, Schuman P. Adrenal insufficiency, recurrent bacteremia, and disseminated abscesses caused by Nocardia asteroides in a patient with acquired immunodeficiency syndrome. Diagn Microbiol Infect Dis. 1996;24:47-51.
30. Baker R, Rook GA, Zumla A. Adrenal function and the hypothalamo-pituitary adrenal axis in immunodeficiency virus-associated tuberculosis. Int J Tuberc Lung Dis: Off J Int Union Tuberc Lung Dis. 1997;1:289-90.
31. Baraia-Etxaburu Artetxe J, Astigarraga Aguirre B, Elorza Olabegova R, Teira Cobo R, Yoldi Arrieta A, Cisterna Cancer R, et al. [Primary adrenal failure and AIDS: report of 11 cases and review of the literature]. Rev Clin Esp. 1998;198:74-9.
32. Radin DR, Esplin JA, Levine AM, Ralls PW. AIDS-related non-Hodgkin's lymphoma: abdominal CT findings in 112 patients. AJR Am J Roentgenol. 1993;160:1133-9.
33. Tappero JW, Conant MA, Wolfe SF, Berger TG. Kaposi's sarcoma. Epidemiology, pathogenesis, histology, clinical spectrum, staging criteria and therapy. J Am Acad Dermatol. 1993;28:371-95.
34. Welch K, Finkbeiner W, Alpers CE, Blumenfeld W, Davis RL, Smuckler EA, et al. Autopsy findings in the acquired immune deficiency syndrome. JAMA. 1984;252:1152-9.
35. Niedt GW, Schinella RA. Acquired immunodeficiency syndrome. Clinicopathologic study of 56 autopsies. Arch Pathol Lab Med. 1985;109:727-34.
36. Zapanti E, Terzidis K, Chrousos G. Dysfunction of the hypothalamic-pituitary-adrenal axis in HIV infection and disease. Hormones (Athens). 2008;7:205-16.
37. Chrousos GP. The stress response and immune function: clinical implications. The 1999 Novera H. Spector Lecture. Ann N Y Acad Sci. 2000;917:38-67.
38. Petrovsky N. Towards a unified model of neuroendocrine-immune interaction. Immunol Cell Biol. 2001;79:350-7.
39. Imura H, Fukata J, Mori T. Cytokines and endocrine function: an interaction between the immune and neuroendocrine systems. Clin Endocrinol (Oxf). 1991;35:107-15.
40. Kageyama K, Tamasawa N, Suda T. Signal transduction in the hypothalamic corticotropin-releasing factor system and its clinical implications. Stress. 2011;14:357-67.
41. Shearer GM, Clerici M, Sarin A, Berzofsky JA, Henkart PA. Cytokines in immune regulation/pathogenesis in HIV infection. CIBA Found Symp. 1995;195:142-7. discussion 147-153.
42. Clerici M. New research hypotheses in the immunopathogenesis of human immunodeficiency virus infection. Q J Nucl Med. 1995;39:163-8.
43. Clerici M, Fusi ML, Ruzzante S, Piconi S, Biasin M, Arienti D, et al. Type 1 and type 2 cytokines in HIV infection - a possible role in apoptosis and disease progression. Ann Med. 1997;29:185-8.
44. Norbiato G, Bevilacqua M, Vago T, Baldi G, Chebat E, Bertora P, et al. Cortisol resistance in acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1992;74:608-13.
45. Norbiato G, Bevilacqua M, Vago T, Clerici M. Glucocorticoids and interferon-alpha in the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1996;81:2601-6.
46. Norbiato G, Bevilacqua M, Vago T, Taddei A, Clerici. Glucocorticoids and the immune function in the human immunodeficiency virus infection: a study in hypercortisolemic and cortisol-resistant patients. J Clin Endocrinol Metab. 1997;82:3260-3.
47. Norbiato G, Bevilacqua M, Vago T, Clerici M. Glucocorticoid resistance and the immune function in the immunodeficiency syndrome. Ann N Y Acad Sci. 1998;840:835-47.
48. Mirani M, Elenkov I, Volpi S, Hiroi N, Chrousos GP, Kino T. HIV-1 protein Vpr suppresses IL-12 production from human monocytes by enhancing glucocorticoid action: potential implications of Vpr coactivator activity for the innate and cellular immunity deficits observed in HIV-1 infection. J Immunol. 2002;169:6361-8.
49. Kino T, Chrousos GP. Human immunodeficiency virus type-1 accessory protein Vpr: a causative agent of the AIDS-related insulin resistance/ lipodystrophy syndrome? Ann N Y Acad Sci. 2004;1024:153-67.
50. Andersen JL, Planelles V. The role of Vpr in HIV-1 pathogenesis. Curr HIV Res. 2005;3:43-51.
51. Sawaya BE, Khalili K, Gordon J, Taube R, Amini S. Cooperative interaction between HIV-1 regulatory proteins Tat and Vpr modulates transcription of the viral genome. J Biol Chem. 2000;275:35209-14.
52. Kino T, Gragerov A, Kopp JB, Stauber RH, Pavlakis GN, Chrousos GP. The HIV-1 virion-associated protein vpr is a coactivator of the human glucocorticoid receptor. J Exp Med. 1999;189:51-62.
53. Wahl LM, Corcoran ML, Pyle SW, Arthur LO, Harel-Bellan A, Farrar WL. Human immunodeficiency virus glycoprotein (gp120) induction of monocyte arachidonic acid metabolites and interleukin 1. Proc Natl Acad Sci U S A. 1989;86:621-5.
54. Raber J, Toggas SM, Lee S, Bloom FE, Epstein CJ, Mucke L. Central nervous system expression of HIV-1 Gp120 activates the hypothalamic-pituitary-adrenal axis: evidence for involvement of NMDA receptors and nitric oxide synthase. Virology. 1996;226:362-73.
55. Pozzoli G, Tringali G, Dello Russo C, Vairano M, Preziosi P, Navarra P. HIV-1 Gp120 protein modulates corticotropin releasing factor synthesis and release via the stimulation of its mRNA from the rat hypothalamus in vitro: involvement of inducible nitric oxide synthase. J Neuroimmunol. 2001;118:268-76.
56. Raffi F, Brisseau JM, Planchon B, Remi JP, Barrier JH, Grolleau JY. Endocrine function in 98 HIV-infected patients: a prospective study. AIDS. 1991;5:729-33.
57. Christeff N, Gharakhanian S, Thobie N, Rozenbaum W, Nunez EA. Evidence for changes in adrenal and testicular steroids during HIV infection. J Acquir Immune Defic Syndr. 1992;5:841-6.
58. Verges B, Chavanet P, Desgres J, Vaillant G, Waldner A, Brun JM, et al. Adrenal function in HIV infected patients. Acta Endocrinol (Copenh). 1989;121:633-7.
59. Membreno L, Irony I, Dere W, Klein R, Biglieri EG, Cobb E. Adrenocortical function in acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1987;65:482-7.
60. Dobs AS, Dempsey MA, Ladenson PW, Polk BF. Endocrine disorders in men infected with human immunodeficiency virus. Am J Med. 1988;84:611-6.
61. Biglino A, Limone P, Forno B, Pollono A, Cariti G, Molinatti GM, et al. Altered adrenocorticotropin and cortisol response to corticotropin-releasing hormone in HIV-1 infection. Eur J Endocrinol. 1995;133:173-9.
62. Hilton CW, Harrington PT, Prasad C, Svec F. Adrenal insufficiency in the acquired immunodeficiency syndrome. South Med J. 1988;81:1493-5.
63. Thaler LM, Blevins Jr LS. The low dose (1-microg) adrenocorticotropin stimulation test in the evaluation of patients with suspected central adrenal insufficiency. J Clin Endocrinol Metab. 1998;83:2726-9.
64. Wolff FH, Nhuch C, Cadore LP, Glitz CL, Lhullier F, Furlanetto TW. Low-dose adrenocorticotropin test in patients with the acquired immunodeficiency syndrome. Braz J Infect Dis. 2001;5:53-9.
65. Foisy MM, Yakiwchuk EM, Chiu I, Singh AE. Adrenal suppression and Cushing's syndrome secondary to an interaction between ritonavir and fluticasone: a review of the literature. HIV Med. 2008;9:389-96.
66. Dort K, Padia S, Wispelwey B, Moore CC. Adrenal suppression due to an interaction between ritonavir and injected triamcinolone: a case report. AIDS Res Ther. 2009;6:10.
67. Mann M, Koller E, Murgo A, Malozowski S, Bacsanyi J, Leinung M. Glucocorticoidlike activity of megestrol. A summary of Food and Drug Administration experience and a review of the literature. Arch Intern Med. 1997;157:1651-6.
68. Subramanian S, Goker H, Kanji A, Sweeney H. Clinical adrenal insufficiency in patients receiving megestrol therapy. Arch Intern Med. 1997;157:1008-11.